Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors

Eleonora Dondossola, Andrey S. Dobroff, Serena Marchiò, Marina Cardó-Vila, Hitomi Hosoya, Steven K. Libutti, Angelo Corti, Richard L. Sidman, Wadih Arap, Renata Pasqualini

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Circulating cancer cells can putatively colonize distant organs to form metastases or to reinfiltrate primary tumors themselves through a process termed "tumor self-seeding." Here we exploit this biological attribute to deliver tumor necrosis factor alpha (TNF), a potent antitumor cytokine, directly to primary and metastatic tumors in a mechanism that we have defined as "tumor self-targeting." For this purpose, we genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells to produce and release murine TNF. In a series of intervention trials, systemic administration of TNF-expressing tumor cells was associated with reduced growth of both primary tumors and metastatic colonies in immunocompetent mice. We show that these malignant cells home to tumors, locally release TNF, damage neovascular endothelium, and induce massive cancer cell apoptosis. We also demonstrate that such tumor-cell-mediated delivery avoids or minimizes common side effects often associated with TNF-based therapy, such as acute inflammation and weight loss. Our study provides proof of concept that genetically modified circulating tumor cells may serve as targeted vectors to deliver anticancer agents. In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery.

Original languageEnglish (US)
Pages (from-to)2223-2228
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number8
DOIs
StatePublished - Feb 23 2016

Fingerprint

Tumor Necrosis Factor-alpha
Neoplasms
Circulating Neoplastic Cells
Lewis Lung Carcinoma
Experimental Melanomas
Antineoplastic Agents
Endothelium
Weight Loss
Adenocarcinoma
Breast
Apoptosis
Cytokines
Neoplasm Metastasis
Inflammation
Growth
Pharmaceutical Preparations

Keywords

  • Apoptosis
  • Endothelial cells
  • Engineered tumor cells
  • Tumor necrosis factor
  • Vascular damaging agent

ASJC Scopus subject areas

  • General

Cite this

Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. / Dondossola, Eleonora; Dobroff, Andrey S.; Marchiò, Serena; Cardó-Vila, Marina; Hosoya, Hitomi; Libutti, Steven K.; Corti, Angelo; Sidman, Richard L.; Arap, Wadih; Pasqualini, Renata.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 8, 23.02.2016, p. 2223-2228.

Research output: Contribution to journalArticle

Dondossola, E, Dobroff, AS, Marchiò, S, Cardó-Vila, M, Hosoya, H, Libutti, SK, Corti, A, Sidman, RL, Arap, W & Pasqualini, R 2016, 'Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors', Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 8, pp. 2223-2228. https://doi.org/10.1073/pnas.1525697113
Dondossola, Eleonora ; Dobroff, Andrey S. ; Marchiò, Serena ; Cardó-Vila, Marina ; Hosoya, Hitomi ; Libutti, Steven K. ; Corti, Angelo ; Sidman, Richard L. ; Arap, Wadih ; Pasqualini, Renata. / Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 8. pp. 2223-2228.
@article{e1277c4e94f34fca94f592219d7cca44,
title = "Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors",
abstract = "Circulating cancer cells can putatively colonize distant organs to form metastases or to reinfiltrate primary tumors themselves through a process termed {"}tumor self-seeding.{"} Here we exploit this biological attribute to deliver tumor necrosis factor alpha (TNF), a potent antitumor cytokine, directly to primary and metastatic tumors in a mechanism that we have defined as {"}tumor self-targeting.{"} For this purpose, we genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells to produce and release murine TNF. In a series of intervention trials, systemic administration of TNF-expressing tumor cells was associated with reduced growth of both primary tumors and metastatic colonies in immunocompetent mice. We show that these malignant cells home to tumors, locally release TNF, damage neovascular endothelium, and induce massive cancer cell apoptosis. We also demonstrate that such tumor-cell-mediated delivery avoids or minimizes common side effects often associated with TNF-based therapy, such as acute inflammation and weight loss. Our study provides proof of concept that genetically modified circulating tumor cells may serve as targeted vectors to deliver anticancer agents. In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery.",
keywords = "Apoptosis, Endothelial cells, Engineered tumor cells, Tumor necrosis factor, Vascular damaging agent",
author = "Eleonora Dondossola and Dobroff, {Andrey S.} and Serena Marchi{\`o} and Marina Card{\'o}-Vila and Hitomi Hosoya and Libutti, {Steven K.} and Angelo Corti and Sidman, {Richard L.} and Wadih Arap and Renata Pasqualini",
year = "2016",
month = "2",
day = "23",
doi = "10.1073/pnas.1525697113",
language = "English (US)",
volume = "113",
pages = "2223--2228",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors

AU - Dondossola, Eleonora

AU - Dobroff, Andrey S.

AU - Marchiò, Serena

AU - Cardó-Vila, Marina

AU - Hosoya, Hitomi

AU - Libutti, Steven K.

AU - Corti, Angelo

AU - Sidman, Richard L.

AU - Arap, Wadih

AU - Pasqualini, Renata

PY - 2016/2/23

Y1 - 2016/2/23

N2 - Circulating cancer cells can putatively colonize distant organs to form metastases or to reinfiltrate primary tumors themselves through a process termed "tumor self-seeding." Here we exploit this biological attribute to deliver tumor necrosis factor alpha (TNF), a potent antitumor cytokine, directly to primary and metastatic tumors in a mechanism that we have defined as "tumor self-targeting." For this purpose, we genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells to produce and release murine TNF. In a series of intervention trials, systemic administration of TNF-expressing tumor cells was associated with reduced growth of both primary tumors and metastatic colonies in immunocompetent mice. We show that these malignant cells home to tumors, locally release TNF, damage neovascular endothelium, and induce massive cancer cell apoptosis. We also demonstrate that such tumor-cell-mediated delivery avoids or minimizes common side effects often associated with TNF-based therapy, such as acute inflammation and weight loss. Our study provides proof of concept that genetically modified circulating tumor cells may serve as targeted vectors to deliver anticancer agents. In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery.

AB - Circulating cancer cells can putatively colonize distant organs to form metastases or to reinfiltrate primary tumors themselves through a process termed "tumor self-seeding." Here we exploit this biological attribute to deliver tumor necrosis factor alpha (TNF), a potent antitumor cytokine, directly to primary and metastatic tumors in a mechanism that we have defined as "tumor self-targeting." For this purpose, we genetically engineered mouse mammary adenocarcinoma (TSA), melanoma (B16-F10), and Lewis lung carcinoma cells to produce and release murine TNF. In a series of intervention trials, systemic administration of TNF-expressing tumor cells was associated with reduced growth of both primary tumors and metastatic colonies in immunocompetent mice. We show that these malignant cells home to tumors, locally release TNF, damage neovascular endothelium, and induce massive cancer cell apoptosis. We also demonstrate that such tumor-cell-mediated delivery avoids or minimizes common side effects often associated with TNF-based therapy, such as acute inflammation and weight loss. Our study provides proof of concept that genetically modified circulating tumor cells may serve as targeted vectors to deliver anticancer agents. In a clinical context, this unique paradigm represents a personalized approach to be translated into applications potentially using patient-derived circulating tumor cells as self-targeted vectors for drug delivery.

KW - Apoptosis

KW - Endothelial cells

KW - Engineered tumor cells

KW - Tumor necrosis factor

KW - Vascular damaging agent

UR - http://www.scopus.com/inward/record.url?scp=84959378208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959378208&partnerID=8YFLogxK

U2 - 10.1073/pnas.1525697113

DO - 10.1073/pnas.1525697113

M3 - Article

VL - 113

SP - 2223

EP - 2228

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -